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Abstract: (1) Purpose: This study aimed to investigate the effects of Mel4 antimicrobial contact lenses
(MACL) on the ocular surface and comfort during extended wear. (2) Methods: A prospective,
randomised, double-masked, contralateral clinical trial was conducted with 176 subjects to evaluate
the biocompatibility of contralateral wear of MACL. The wearing modality was 14-day extended
lens wear for three months. The participants were assessed at lens dispensing, after one night, two
weeks, one month and three months of extended wear and one month after study completion. (3)
Results: There were no significant differences (p > 0.05) in ocular redness or palpebral roughness
between Mel4 and control eyes at any of the study visits. There was no significant difference (p > 0.05)
in corneal staining between Mel4 and control eyes. There were no significant differences in front
surface wettability or deposits or back surface debris (p > 0.05). No statistically significant differences
(p > 0.05) were found in comfort, dryness, CLDEQ-8 scores lens or edge awareness. There was no
evidence for delayed reactions on the ocular surface after cessation of lens wear. (4) Conclusion: The
novel MACLs showed similar comfort to control lenses and were biocompatible during extended
wear. Thus, these lenses were compatible with the ocular surface.
Keywords: Mel4 peptide; antimicrobial contact lens; extended wear; biocompatibility; comfort;
clinical trail
1. Introduction
Contact lens wear can be associated with inflammatory and infective responses, trig-
gered by microbial colonisation of contact lenses. These are major concerns for contact
lens wearers and practitioners. The development of contact lenses with antimicrobial
activity may inhibit microbial adhesion and so reduce contact-lens-related inflammation
and infection. Several antimicrobial contact lenses have been developed and tested in labo-
ratory models. These include contact lenses containing silver [1–3], inhibitors of bacteria
quorum-sensing systems [4], poly-epsilon lysine [5] and nitric-oxide-releasing lenses [6]. A
cationic, peptide-coated (melimine) contact lens has also been developed that showed good
antimicrobial activity in vitro [7], prevented bacterially-driven adverse events associated
with contact lens wear in animal models [8,9] and was generally safe to wear in humans,
although it was associated in some wearers with low levels of corneal staining [10]. Due to
this latter issue, the cationic peptide melimine was shortened to make Mel4 [11].
Mel4, a small, cationic, antimicrobial peptide, has high antimicrobial activity against
Pseudomonas aeruginosa and Staphylococcus aureus in solution and when immobilised on
surfaces [12]. It has been successfully coated onto hydrogel and silicone hydrogel contact
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lenses [12–14] and shown to be active against other bacteria such as Stenotrophomonas
maltophilia and Delftia acidovorans. The Mel4-coated lenses were safe in a rabbit model of
daily contralateral wear [13,14]. In addition, a phase I, human clinical trial showed no corneal
fluorescein staining and no increase in ocular redness after one week of daily wear [13].
A phase II/III clinical trial on the Mel4-coated contact lenses was conducted at the
LV Prasad Eye Institute in Hyderabad, India, and the biocompatibility of the lenses is
addressed in the current manuscript. The main aim of this trial was to assess whether
the Mel4-coated lenses could reduce the incidence of corneal inflammatory events during
extended wear. These lenses resulted in a reduction in the incidence of corneal inflammatory
events by 69% [15]. These Mel4-coated lenses had similar levels and types of microbes
isolated from them and from eyes wearing them compared to the control lenses [16].
It is also valuable to investigate the biocompatibility and comfort of Mel4-coated
contact lenses on the extended wear modality. Thus, the aim of the current study was
to investigate the biocompatibility and comfort of Mel4-coated contact lenses during the
phase II/III, extended wear, human clinical trial. The hypotheses of this study were that
the Mel4-coated contact lenses are compatible and comfortable during extended wear.
2. Results
2.1. Assessment of Activity of Mel4-Coated Lenses Prior to Lens Wear
The data for the amount of Mel4 on contact lenses and the ability of lenses to inhibit
the adhesion of Pseudomonas aeruginosa and Staphylococcus aureus have been previously
published [15]. Briefly, randomly selected contact lenses from each batch that was produced
were selected for measurement. These Mel4-coated lenses contained 62.6 ± 26.4 µg of amino
acids per lens and significantly reduced the adhesion of P. aeruginosa and S. aureus by >1.8
log10 CFU/lens (p < 0.001) compared to control uncoated lenses [15]. This demonstrated
that the participants in the trial were prescribed with active Mel4-coated contact lenses.
2.2. Subject Demographics
The demographic and biometric data for the subjects who were dispensed with study
lenses are summarised in Table 1. Slightly more males (108/208; 52%) were enrolled and
were dispensed with study lenses (93/176; 53%) than females. Additionally, a greater
number of neophytes (160/208; 77%) were enrolled and were dispensed with study lenses
(128/176; 73%). There was no difference in the refractive errors, keratometry and contact
lens powers between the Mel4- and control-lens-wearing eyes in both enrolled (p > 0.05)
and study-lens-dispensed subjects (p > 0.05).
Table 1. Demographic and biometric data of subjects dispensed with study lenses.
Demographic and Biometric Details Subjects Dispensed with Study Lenses (n = 176)
Mel4-Lens-Wearing Eye Control-Lens-Wearing Eye p-Value
Age (years): Mean ± SD
Range
22.6 ± 4.2
18 to 42 -
Gender (Male:Female) 93:83 -
Refractive error-Sphere (Ds) 1: Mean ± SD; Range −2.82 ± 1.44−0.50 to −6.50
−2.80 ± 1.46
−0.50 to −6.50 0.528
Refractive error-Cylinder (Dc): Mean ± SD; Range −0.25 ± 0.35−0.25 to −1.50
−0.22 ± 0.35
−0.25 to −1.50 0.249
Keratometry-Flat (D): Mean ± SD; Range 43.02 ± 1.4437.50 to 47.25
43.01 ± 1.46
37.50 to 47.25 0.663
Keratometry-Steep (D): Mean ± SD; Range 43.76 ± 1.5838.75 to 48.50
43.71 ± 1.58
38.75 to 48.50 0.105
Contact lens wearer (Neophyte:Experienced lens wearer) 128:48 -
Contact lens base curve (8.3:8.7) mm 106:70 -
Contact lens power (Ds): Mean ± SD; Range −2.84 ± 1.36−1.00 to −6.00
−2.84 ± 1.39
−1.00 to −6.00 0.869
1 D = diopter.
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2.3. Clinical Lens Surface Characteristics
The lens surface characteristics of Mel4 and control contact lenses are presented in
Table 2. There were no significant differences in front surface wettability between Mel4
and control lenses during all the visits (p > 0.05), with values ranging from 3.7 to 3.5 units.
The front surface wetting for both Mel4 and control lenses decreased by 0.1–0.2 units over
the course of the study, and this was significant (p = 0.001). There were no significant
differences seen either in front surface deposits (p > 0.05) or back surface debris (p > 0.05)
across all the study visits between both lens types. The front surface deposits for both lens
types increased over the course of the study by between 0.1 and 0.5 units (p = 0.001), and
the back surface debris significantly increased over the course of the study by between 0.1
and 0.3 units (p = 0.001).







Mel4 Lens Control Lens Linear Mixed Model






Dispensing 176 3.7 ± 0.6 3.7 ± 0.6
0.593 0.001 0.513
1N 165 3.6 ± 0.6 3.7 ± 0.5
2W 153 3.6 ± 0.3 3.6 ± 0.3
1M 144 3.6 ± 0.3 3.5 ± 0.3




Dispensing 176 0.2 ± 0.3 0.2 ± 0.3
0.896 0.001 0.996
1N 165 0.3 ± 0.4 0.3 ± 0.4
2W 153 0.6 ± 0.5 0.6 ± 0.5
1M 144 0.6 ± 0.6 0.6 ± 0.6




Dispensing 176 0.1 ± 0.2 0.1 ± 0.2
0.715 0.001 0.857
1N 165 0.2 ± 0.2 0.2 ± 0.2
2W 153 0.3 ± 0.4 0.3 ± 0.4
1M 144 0.4 ± 0.5 0.4 ± 0.5
3M 128 0.4 ± 0.5 0.4 ± 0.5
* 1N = 1 night of lens wear, 2W = 2 weeks of lens wear, 1M = 1 month on lens wear, 3M = 3 months of lens wear.
2.4. Lens Fit Characteristics
The lens fit characteristics of Mel4 and control contact lenses are presented in Table 3.
There were no significant differences in any lens fit characteristics between Mel4 and
control contact lenses over the course of the study. The average overall lens acceptance
score for both the lens types at each visit was 3.8 which indicated good centration, complete
coverage, acceptable tightness of the lens and adequate lens movement and lens lag. No
lens was refitted during the study period because of any lens fit issues. There were small
but statistically significant differences between the visits for primary gaze movement, lag,
tightness and overall acceptance (p < 0.05). There was no significant difference between the
visits for lens centration (p ≥ 0.05). No mucin balls were seen with either of the lens types
at any of the visits.
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(−1 to +1, 0.1 mm)
Lens Dispensing 176 0 (−0.3–0.2) 0 (−0.3–0.2)
0.589 0.409 0.950
1N 165 0 (−0.5–0.3) 0 (−0.5–0.3)
2W 153 0 (−0.3–0.2) 0 (−0.3–0.2)
1M 144 0 (−0.5–0.2) 0 (−0.5–0.0)
3M 128 0 (−0.3–0.2) 0 (−0.3–0.2)
Centration
Y-axis
(−1 to +1, 0.1 mm)
Lens Dispensing 176 0 (−0.3–0.5) 0 (−0.3–0.3)
0.595 0.118 0.266
1N 165 0 (−0.4–0.5) 0 (−0.3–0.5)
2W 153 0 (−0.3–0.5) 0 (−0.3–0.5)
1M 144 0 (−0.4–0.4) 0 (−0.3–0.4)
3M 128 0 (−0.2–0.3) 0 (−0.2–0.3)
Primary gaze movement
(0–10, 0.1)
Lens Dispensing 176 0.4 ± 0.1 0.4 ± 0.1
0.988 0.049 0.752
1N 165 0.4 ± 0.1 0.4 ± 0.1
2W 153 0.4 ± 0.1 0.4 ± 0.1
1M 144 0.4 ± 0.1 0.4 ± 0.1
3M 128 0.4 ± 0.1 0.4 ± 0.1
Primary gaze lag
(0–10, 0.1)
Lens Dispensing 176 0.1 ± 0.1 0.1 ± 0.1
1.000 0.005 -
1N 165 0.1 ± 0.1 0.1 ± 0.1
2W 153 0.1 ± 0.1 0.1 ± 0.1
1M 144 0.2 ± 0.1 0.2 ± 0.1
3M 128 0.2 ± 0.1 0.2 ± 0.1
Tightness
(0–100, 1)%
Lens Dispensing 176 41 ± 3 41 ± 3
0.817 0.001 0.968
1N 165 41 ± 3 41 ± 3
2W 153 42 ± 3 42 ± 3
1M 144 41 ± 3 41 ± 3
3M 128 42 ± 3 42 ± 3
Overall acceptance
(0–4, 0.1)
Lens Dispensing 176 3.8 ± 0.1 3.8 ± 0.1
0.410 0.001 0.380
1N 165 3.8 ± 0.1 3.8 ± 0.1
2W 153 3.8 ± 0.1 3.8 ± 0.1
1M 144 3.8 ± 0.1 3.8 ± 0.1
3M 128 3.8 ± 0.1 3.8 ± 0.1
* 1N = 1 night of lens wear, 2W = 2 weeks of lens wear, 1M = 1 month on lens wear, 3M = 3 months of lens wear.
2.5. Ocular Physiology
The conjunctival redness and roughness of the Mel4 and control lens wearing eye at
the 1N, 2W, 1M and 3M study visits are presented in Table 4. There was no significant
difference in bulbar redness (p > 0.7), limbal redness (p > 0.9), palpebral redness (p > 0.6) or
palpebral roughness (p > 0.3) between Mel4- and control-contact-lens-wearing eyes in any
of the study visits. All of these variables slightly but significantly (p = 0.001) increased by
between 0.1 and 0.2 units over the course of the study. Similarly, there were no significant
differences in lens-induced conjunctival staining (p = 1.0) or indentation (p > 0.1) between
the Mel4-lens-wearing eye and control-lens-wearing eye (Table 4). There were no significant
differences (p > 0.35) in central, nasal, temporal or superior corneal staining (extent, depth
or type) between Mel4- and control-contact-lens-wearing eyes (Table 5). None of these
corneal-staining characteristics changed during the study (p ≥ 0.2).
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1N 167 1.5 ± 0.2 1.5 ± 0.2
0.758 0.001 0.135
2W 153 1.5 ± 0.2 1.5 ± 0.2
1M 144 1.6 ± 0.2 1.6 ± 0.2
3M 129 1.6 ± 0.2 1.6 ± 0.2
Limbal Redness
(0–4, 0.1)
1N 167 1.2 ± 0.3 1.2 ± 0.3
0.961 0.001 0.660
2W 153 1.2 ± 0.2 1.2 ± 0.2
1M 144 1.3 ± 0.3 1.3 ± 0.3
3M 129 1.4 ± 0.2 1.4 ± 0.2
Palpebral Redness
(0–4, 0.1)
1N 167 1.5 ± 0.2 1.6 ± 0.2
0.610 0.001 0.053
2W 153 1.6 ± 0.3 1.6 ± 0.3
1M 144 1.6 ± 0.3 1.6 ± 0.3
3M 129 1.7 ± 0.3 1.7 ± 0.3
Palpebral Roughness
(0–4, 0.1)
1N 167 1.2 ± 0.3 1.3 ± 0.3
0.388 0.001 0.574
2W 153 1.3 ± 0.3 1.3 ± 0.3
1M 144 1.3 ± 0.3 1.3 ± 0.3




1N 167 0.2 ± 0.2 0.2 ± 0.2
1.000 0.001 1.000
2W 153 0.2 ± 0.3 0.2 ± 0.2
1M 144 0.3 ± 0.3 0.3 ± 0.3




1N 167 0.1 ± 0.1 0.1 ± 0.1
0.112 0.001 0.041
2W 153 0.1 ± 0.2 0.1 ± 0.2
1M 144 0.1 ± 0.2 0.1 ± 0.2
3M 129 0.1 ± 0.2 0.1 ± 0.2
* 1N = 1 night of lens wear, 2W = 2 weeks of lens wear, 1M = 1 month on lens wear, 3M = 3 months of lens wear.


















1N 162 0 (0–0) 0 (0–0)
0.674 0.200 0.632
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–0) 0 (0–1)
3M 129 0 (0–1) 0 (0–1)
Centre
(Depth; 0–4, 1)
1N 162 0 (0–0) 0 (0–0)
0.674 0.200 0.632
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–0) 0 (0–1)
3M 129 0 (0–1) 0 (0–1)
Centre
(Type; 0–4, 0.5)
1N 162 * 0 (0–0) 0 (0–0)
0.674 0.200 0.632
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–0) 0 (0–1)
3M 129 0 (0–1) 0 (0–1)
Nasal
(Extent; 0–4, 1)
1N 162 0 (0–1) 0 (0–1)
0.670 0.426 0.262
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–0) 0 (0–1)
Nasal
(Depth; 0–4, 1)
1N 162 0 (0–1) 0 (0–1)
0.869 0.421 0.254
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–0) 0 (0–1)



















1N 162 0 (0–1) 0 (0–1.5)
0.586 0.386 0.342
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–0) 0 (0–1)
Temporal
(Extent; 0–4, 1)
1N 162 0 (0–1) 0 (0–1)
0.856 0.437 0.457
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–0) 0 (0–1)
3M 129 0 (0–1) 0 (0–0)
Temporal
(Depth; 0–4, 1)
1N 162 0 (0–1) 0 (0–1)
0.856 0.437 0.457
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–0) 0 (0–1)
3M 129 0 (0–1) 0 (0–0)
Temporal
(Type; 0–4, 0.5)
1N 162 0 (0–1) 0 (0–1)
0.780 0.340 0.498
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–0) 0 (0–0.5)
3M 129 0 (0–1) 0 (0–0)
Superior
(Extent; 0–4, 1)
1N 162 0 (0–0) 0 (0–1)
0.368 0.242 0.362
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–1) 0 (0–1)
Superior
(Depth; 0–4, 1)
1N 162 0 (0–0) 0 (0–1)
0.368 0.242 0.362
2W 153 0 (0–1) 0 (0–1)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–1) 0 (0–1)
Superior
(Type; 0–4, 0.5)
1N 162 0 (0–0) 0 (0–1)
0.649 0.151 0.258
2W 153 0 (0–1) 0 (0–0.5)
1M 144 0 (0–1) 0 (0–1.5)
3M 129 0 (0–1) 0 (0–1)
Inferior
(Extent; 0–4, 1)
1N 162 0 (0–1) 0 (0–1)
0.119 0.238 0.337
2W 153 0 (0–1) 0 (0–2)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–2) 0 (0–2)
Inferior
(Depth; 0–4, 1)
1N 162 0 (0–1) 0 (0–1)
0.119 0.238 0.337
2W 153 0 (0–1) 0 (0–2)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–2) 0 (0–2)
Inferior
(Type; 0–4, 0.5)
1N 162 0 (0–1) 0 (0–1)
0.119 0.238 0.337
2W 153 0 (0–1) 0 (0–2)
1M 144 0 (0–1) 0 (0–2)
3M 129 0 (0–2) 0 (0–2)
* 1N = 1 night of lens wear, 2W = 2 weeks of lens wear, 1M = 1 month on lens wear, 3M = 3 months of lens wear.
2.6. Subjective Ratings
The subjective ratings of the comfort at each visit are presented in Table 6. There
was no significant difference (p > 0.1) in the subjective ratings of overall comfort, dryness
or lens edge awareness between Mel4- and control-lens-wearing eyes. Overall comfort
significantly (p = 0.001) decreased for both lens types from the 1N to the 3M visits, dropping
by 3–4 points, as did overall dryness (p = 0.001) which increased by 5 points.
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1N 167 92 ± 8 92 ± 8
0.770 0.001 0.556
2W 153 91 ± 7 91 ± 8
1M 144 90 ± 7 91 ± 9
3M 129 88 ± 8 89 ± 7
Overall dryness
(1–100, 1)
1N 167 8 ± 5 8 ± 5
0.789 0.001 0.742
2W 153 11 ± 11 11 ± 11
1M 144 11 ± 11 12 ± 12
3M 129 13 ± 11 13 ± 11
Edge awareness
(0–10, 1)
1N 165 1 (1–2) 1 (1–2)
0.135 0.077 0.969
2W 153 1 (1–4) 1 (1–5)
1M 144 1 (1–3) 1 (1–3)
3M 128 1 (1–3) 1 (1–3)
Lens awareness
(0–10, 1)
1N 165 1 (1–2) 1 (1–2)
0.139 0.471 0.858
2W 153 1 (1–4) 1 (1–4)
1M 144 1 (1–3) 1 (1–3)
3M 128 1 (1–3) 1 (1–3)
* 1N = 1 night of lens wear, 2W = 2 weeks of lens wear, 1M = 1 month on lens wear, 3M = 3 months of lens wear.
All subjects were asked to score the modified CLDEQ-8 questionnaires at the one-
month and three-month visit. One hundred and thirty-nine subjects scored the question-
naires at the first month’s visit and 126 subjects scored the questionnaires at the three-month
visit. There were no significant differences in CLDEQ-8 scores between Mel4- and control-
lens-wearing eyes at either the one- (p = 0.5) or three-month visit (p = 0.9) (Figure 1).
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Figure 1. Comfort of contact lenses during wear measured with the modified CLDEQ-8.
2.7. Ocular Responses One Month after Cessation of Lens Wear
The ocular responses at the four-month visit, i.e., one month after cessation of lens
wear, are provided i Supplementary Table S2. There were no statistical differences between
the Mel4-lens-wearing eyes and the control-lens-wearing eyes for any of the clinical or
subjective variables. There were some small but significant differences between the study
visits for conjunctival bulbar, limbal and palpebral redness (p = 0.001), which had increased
by 0.1 to 0.2 units, and palpebral roughness (p = 0.001), which had increased by 0.1 unit.
There was also a very small but significant change in inferior corneal staining (extent,
depth and type; p ≤ 0.016), which had increased by less than a unit interval. Overall,
ocular comfort was slightly but significantly (p = 0.001) decreased at the four-month visit
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by 3 units. As each of these differences were not different between lenses and there were
no lens/visit interactions in the statistical analyses, these changes were likely the result of
lens wear rather than the result of wearing either Mel4-coated or control lenses.
2.8. Ocular Responses of Participants Who Dropped out of Lens Wear during the Study Compared
to Those Who Completed the Study
The ocular and subjective responses of the participants who dropped out of lens wear
during the study compared to those who completed the study at different study visits are
provided in Supplementary Table S3. The responses collected from four participants at
the 1N visit that had dropped out by the 2W visit were compared to the participants who
remained wearing lenses at the 2W visit (153). Similarly, two participants at the 2W visit
that had dropped out by the 1M visit and their responses were compared to the participants
who remained wearing lenses at the 1M visit (144), and two participants at the 1M visit that
had dropped out by the 3M visit were compared to the participants who remained wearing
lenses at the 3M visit (129). There were no clinical differences in ocular and subjective
responses between dropouts and those who remained in Mel4 or control lenses. The lens
surface characteristics and lens fit characteristics of the participants who dropped out of
lens wearing during the study compared to those who completed the study at different
study visits are provided in Supplementary Table S4. There were no clinical differences
in lens surface characteristics and lens fit characteristics between dropouts and those who
remained in Mel4 or control lenses.
3. Discussion
This study investigated the biocompatibility and comfort of Mel4-coated contact lenses
in a human, three-month, extended wear clinical trial. Overall, in comparison to the eyes
wearing control, uncoated, etafilcon A lenses, Mel4-coated lenses had no worse effect on the
biocompatibility and comfort during lens wear than the uncoated lenses. This indicates that
Mel4-coated lenses are not prone to forming more deposits, wet as well as control lenses,
do not affect lens parameters that could influence centration, movement or tightness and
do not induce inflammation as measured by changes in redness or conjunctival or corneal
staining or comfort during lens wear. This is in agreement with a one-week study of daily
wear with Mel4-coated lenses [13] and is similar to results reported for other antimicrobial
lenses that had been made using a fimbrolide [4] or another cationic, antimicrobial peptide
(a forerunner of Mel4), melimine [10]. Wearing Mel4-coated contact lenses over a three-
month period did not result in any delayed ocular reactions as the data from the 4M visit,
at which time the participants had been not wearing Mel4-coated lenses for one month
(but had returned to their habitual method for correcting their refractive error), were not
different between the Mel4- or control-lens-wearing eyes.
This study found no significant fluorescein staining (extent, depth and type) of the
cornea following lens wear of Mel4-coated lenses, which is similar to the study on Mel4-
coated lenses worn on a daily-wear basis for a week [13] and fimbrolide-coated lenses after
20 to 22 h of lens wear [4]. However, this does contrast with a study of melimine-coated
contact lenses which were associated with corneal staining [10]. The current study confirms
that the change in amino acid sequence between melimine (TLISWIKNKRKQRPRVSR-
RRRRRGGRRRR) and Mel4 (KNKRKRRRRRRGGRRRR) eliminated the corneal punctate
staining that occurred with melimine-coated lenses. The change from melimine to Mel4
removed several amino acids. Tryptophan (W) is present in the amino acid sequence of
melimine at position five. Also present in melimine, are other hydrophobic amino acids
such as isoleucine (I, two residues at positions 3 and 6), glycine (G, two residues at posi-
tions 24 and 25), valine (V, one residue at position 16), leucine (L, one residue at position 2)
and proline (P, one residue at position 14). None of these amino acids are in Mel4. It is
possible that one or more of these might have been involved in interactions with human
corneal cells. The amino acid tryptophan (W) is often present in proteins that reside within
membranes [17,18] which indicates its potential to interact with membranes. Additionally,
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tryptophan in arginine-rich peptides facilitates the translocation of these peptides through
membranes [19].
Similar to melimine coating [7], the Mel4 coating (22.7◦ ± 5.0) has previously been
shown to significantly improve the wettability of etafilcon A lenses (69.3◦ ± 14.6) when
measured using the advancing contact angle technique in the laboratory [13]. This reinforces
previous findings that wettability measured in the laboratory does not translate to improved
comfort responses [20] as there was no difference in comfort between Mel4-coated and
control lenses. Fimbrolide-coated lenses [4] have been associated with increased dryness,
lens edge and lens awareness and were slightly less comfortable to wear. In the current
study, also there was no significant difference in dryness, lens edge and lens awareness
between Mel4-coated and control lenses, similar to the study of Mel4-coated lenses [13]
used on a daily-wear basis for a week or melimine-coated lenses [10] when worn for a
day. The reason for the improved comfort response with Mel4-coated lenses compared to
fimbrolide lenses may be due to the different antimicrobial compounds themselves, the
different chemistries used to attach fimbrolide and Mel4 to lenses or the different lenses
used (hydrogel etafilcon A vs. silicone hydrogel lotrafilcon A).
To understand whether dropout from this clinical trial at any stage was associated
with differences in the ocular surface or lens characteristics of the people who dropped
out compared to those that completed the trial, variables of those who dropped out were
compared to those who remained in the trial at each visit and at the final 3-month visit. This
demonstrated that the people who dropped out did not have any significant differences
in ocular surface responses, lens characteristics or comfort. This further reinforces the
biocompatibility of Mel4 during lens wear.
4. Materials and Methods
4.1. Study Design and Participants
The study design, inclusion and exclusion criteria were identical to a previous study [16].
Briefly, a total of 176 participants who met the inclusion/exclusion criteria were dispensed
with study lenses. Participants were randomly assigned to wear a Mel4 antimicrobial
contact lens (MACL) in one eye and a control lens (uncoated etafilcon A) in the contralateral
eye. All the participants were instructed to replace lenses every two weeks during three
months of extended wear. To reduce the possibility of participants mixing right- and
left-eye lenses, the right-eye and left-eye lens vials were affixed with green and white labels,
respectively. If the participants needed to remove their lenses temporarily, they were given
Biotrue contact lens care solution (Bausch and Lomb, Rochester, NY, USA) and a case only
for temporary storage.
4.2. Production and Quantification of Mel4 Peptide Attached to Contact Lenses
Etafilcon A contact lenses (Acuvue2®, Johnson and Johnson Vision Care Inc., Jack-
sonville, FL, USA) were used for this study. Mel4 peptide (amino acid sequence: KNKRKR-
RRRRRGGRRRR; American Peptide Company, Sunnyvale, CA, USA) was synthesised by
conventional solid-phase peptide synthesis with >95% purity. The procedure for cova-
lently attaching Mel4 to contact lenses has been reported elsewhere [10,13,16]. Control,
uncoated (etafilcon A) lenses were removed from their packs, washed and autoclaved prior
to use. Mel4-coated lenses for the clinical trial were produced in different batches. After
the production of each batch and prior to the lens dispensing visit, two Mel4-coated lenses
from each batch were assessed by amino acid analysis to confirm the presence and amount
of peptide on to the lens surface [12,13,21]. The sum of all the amino acids derived from
each contact lens was regarded as the total amount of peptide attachment to a contact lens.
Similarly, two Mel4-coated and control lenses from each batch were assessed for adhesion
of P. aeruginosa (ATCC 27853) and S. aureus (L2260/15). The bacterial adhesion protocol has
been reported previously [7,12].
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4.3. Clinical Procedures
A total of seven visits were undertaken; baseline (visit 1), lens dispensing (visit 2),
after one night (visit 3), 2 weeks, (visit 4), 1 month (visit 5) and 3 months of lens wear (visit
6), followed by a 1-month follow-up visit after study lens discontinuation (visit 7). The
seventh follow-up visit at the end of 3 months’ extended wear included no assigned contact
lens wear, and the subjects were free to wear their glasses if desired to test for any delayed
responses to the investigational product. At each scheduled visit, the ocular characteristics
and subjective responses of each participant were assessed. Slit-lamp biomicroscopy was
performed for anterior eye assessment including contact lens fit, lens surface characteristics,
ocular redness (bulbar, limbal and palpebral), palpebral roughness, conjunctival and corneal
staining. Contact lens fitting (assessed using the push-up test) and contact lens deposits
during wear were measured according to previously described methods [22,23] All of the
clinical grading was conducted using the Cornea and Contact Lens Research Unit grading
scales [24] (0 to 4 units) interpolated into 0.1 increments, except for corneal staining which
was graded in 1.0 steps for extent and depth and 0.5 steps for type. Concordance training
for the optometrists was conducted before study commencement, and concordance was
measured every 6 months during the study. All optometrists were allowed to examine study
participants if they scored more than 70% concordance for each grading scale, and they were
retrained if concordance dropped below this level. All optometrists were masked to which
eye of each participant was wearing which contact lenses. The CLDEQ-8 questionnaire was
modified for monocular lens wear (see Supplementary Table S1).
4.4. Statistical Analysis
Data were analysed using Microsoft® Office Excel®, Graph Pad Prism 7.02 (Graph
Pad Software Inc., San Diego, CA, USA) and IBM SPSS (Package for the Social Sciences
software) for Windows software v24.0 (SPSS, Inc., Chicago, IL, USA). According to central
limit theorem, [25] this study, with its large sample collection of ordinal variables, can be
assumed to have a normal distribution; thus, the means of the variables were reported
with standard deviation. Non-ordinal variables were described as median and range. The
comparisons of clinical and lens variables at each visit between Mel4- and control-lens-
wearing eyes were examined using linear mixed models (LMM). As some subjects dropped
out of lens wear during the study and there were some other cases of missing data, the
sample size varied among the study visits and so LMM analyses were conducted. Post
hoc t-tests with Bonferroni correction were used to assess significant changes over time
and between both lens-wear types. For the subjects who dropped out of the study, where
data had been collected, this was compared to the subjects who remained in the study
to determine whether changes to ocular surface physiology or comfort during wear may
have influenced the decision to drop out of the study. For all tests, the level of statistical
significance was maintained at p < 0.05.
5. Conclusions
In conclusion, wearing Mel4-coated contact lenses did not affect the ocular responses,
contact lens deposition or other characteristics or comfort during lens wear. These data,
combined with the fact that the Mel4-coated lenses did not affect the normal ocular micro-
biota during wear [16] and could reduce the number of corneal infiltrative events during
extended contact lens wear [15], indicate that Mel4 coatings are biocompatible and useful
to control microbially-driven adverse events.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/antibiotics11010058/s1, Table S1: Modified CLDEQ-8 questionnaire
for monocular lens wear, Table S2: Ocular and subjective responses at baseline visit prior to lens
wear and at the 4M study visit, one month after cessation of contact lens wear, Table S3: Ocular and
subjective responses at dropouts and completed visits, Table S4: Lens surface characteristics and fit
characteristics of Mel4 and control contact lenses at dropouts and completed visits.
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